findmyKOL

Anju Nohria, MD

Enriched profile

Director of the Cardio-Oncology Program, NYU Langone Hospitals - Manhattan; Faculty Member, Department of Medicine, NYU Grossman School of Medicine · NYU Langone Health

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyCardiovascular DiseaseFocusChemotherapy-induced cardiotoxicity and mitigation+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Anju Nohria is Director of the Cardio-Oncology Program, NYU Langone Hospitals - Manhattan; Faculty Member, Department of Medicine, NYU Grossman School of Medicine at NYU Langone Health. OpenAlex indexes 331 publications with 14,939 citations (h-index 62); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 9 Oct 2026

Overview

Updated 14 Oct 2026

Anju Nohria, MD, is Director of the Cardio-Oncology Program, NYU Langone Hospitals - Manhattan at NYU Langone Health. The public record shows 331 publications with 14,939 citations (h-index 62), centered on Chemotherapy-induced cardiotoxicity and mitigation, Heart Failure Treatment and Management, Cardiac tumors and thrombi. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 6 companies.

  • Most recent indexed publication: 2026 · Circulation
  • Top research focus: Chemotherapy-induced cardiotoxicity and mitigation
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Heart Failure2 trialsChronic Kidney Disease1 trialRenal Insufficiency1 trialCarotid Stenosis1 trialConstriction, Pathologic1 trialLymphoma1 trial

Research focus

OpenAlex concept fingerprint
Chemotherapy-induced cardiotoxicity and mitigationHeart Failure Treatment and ManagementCardiac tumors and thrombiCardiovascular Function and Risk FactorsCancer Immunotherapy and Biomarkers

Drugs & molecules

across trials, industry payments and publications
Jardiancegeneric · EmpagliflozinClinical trials—Industry payments1Publications—Lumoxitigeneric · Moxetumomab pasudotoxClinical trials—Industry payments1Publications—Orgovyxgeneric · RelugolixClinical trials—Industry payments1Publications—SotalolClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments15AstraZeneca UK LimitedClinical trials—Industry payments8AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2Brigham and Women's HospitalClinical trials2Industry payments—Abbott Medical DevicesClinical trials1Industry payments—AltaThera Pharmaceuticals LLCClinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Dana-Farber Cancer InstituteClinical trials1Industry payments—Sumitomo Pharma America, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
331publications

Distinct works indexed by OpenAlex, matched via ORCID; 15 in PubMed.

14,939citations

Total citations across indexed works.

62h-index

Hirsch index (OpenAlex). i10-index 142.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
6companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    79.9%
    Statin20.8%
    Atorvastatin Calcium54%Rosuvastatin Calcium31%Pravastatin Sodium12%Simvastatin3%
    Part D≥197 patients
    Beta blocker18.8%
    Metoprolol Succinate53%Carvedilol26%Bisoprolol Fumarate9%Atenolol4%Labetalol Hcl4%Sotalol2%Metoprolol Tartrate2%
    Part D<11 patients

    + 18 more classes in this area

  • Metabolism & gastrointestinal

    8.4%
    SGLT2 inhibitor4.3%
    Jardiance91%Farxiga10%
    Part D<11 patients
    Potassium supplement1.7%
    Potassium Chloride88%Klor-Con M2012%
    Part D<11 patients

    + 5 more classes in this area

  • Blood & clotting

    7.9%
    Factor Xa inhibitor7.1%
    Eliquis87%Xarelto13%
    Part D≥100 patients
    P2Y12 inhibitor0.7%
    Clopidogrel100%
    Part D≥13 patients

    + 1 more class in this area

All 9 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)94.1% facility · 5.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 14 Oct 2026

18 congress contributions (2010–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Sarju Ganatra53Tomas G. Neilan48Lynne Warner Stevenson43John D. Groarke38Sourbha S. Dani31Ana Barac29Kerry Lynn Reynolds28Michael M. Givertz28Michael G. Fradley26Paaladinesh Thavendiranathan26Eldrin Foster Lewis24Syed Mahmood21Ryan Joseph Sullivan19Osnat Itzhaki Ben Zadok19Leyre Zubiri19James Chen-Tson Fang18Daniel John Lenihan18Alexander Richard Lyon18Danielle S. Bitterman17Katelyn M. Atkins17Marcelo F. Di Carli17Raymond H. Mak16Daniel A. Zlotoff16Lili Zhang16Sumanth Khadke15Franck Thuny15Jon Mark Hainer14Sachin P. Shah14Lucie Heinzerling14Stéphane Éderhy14Gilbert H. Mudge14Amna Zafar14Eric H. Yang14Salim S. Hayek14Akshay Suvas Desai14Dipti Gupta13Javid J. Moslehi13Zsófia D. Drobni13Sui W. Tsang13Malek Z. O. Hassan12

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board certified

    American Board of Internal Medicine: Advanced Heart Failure and Transplant Cardiology

    2014
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
  • Board certified

    American Board of Internal Medicine: Cardiovascular Disease

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
  • MD

    Harvard University

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗

Secondary affiliations

appointments beyond the home institution
  • Perlmutter Cancer Center

    NYU Langone (34th Street office)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.